AcelRx Pharmaceuticals Inc (NASDAQ:ACRX)
| 0.69 BATS BZX Real-Time Price As of Mar 28 |  0.00 / 0.00%Today’s Change | 0.57 Today|||52-Week Range 7.60 | -69.47% Year-to-Date |
Five Year Financial Summary
| All Currency in US Dollars | 4 Quarter Trend | |||||
|---|---|---|---|---|---|---|
| Quarter 3 2018 | Quarter 4 2018 | Quarter 1 2019 | Quarter 2 2019 | |||
| Operating Activities | Net Income / Starting Line | -12.5M | -12.6M | -13.7M | -12.4M | |
| Depreciation | 142.0K | 140.0K | 328.0K | 406.0K | ||
| Total Other Cash Flow | 4.7M | 2.9M | 2.6M | 384.0K | ||
| Funds From Operations | -7.6M | -9.6M | -10.8M | -11.6M | ||
| Funds From/For Other Operating Expenses | -1.3M | -578.0K | 2.5M | 697.0K | ||
| Net Cash Flow - Operating Activities | -6.3M | -9.0M | -13.2M | -12.3M | ||
| Investing | Increase In Investments | 0.00 | -17.7M | -3.9M | -24.3M | |
| Decrease In Investments | 10.9M | 6.0M | 4.9M | 14.8M | ||
| Capital Expenditures | -186.0K | -246.0K | -658.0K | -1.1M | ||
| Net Cash Flow Investing | 10.7M | -12.0M | 371.0K | -10.6M | ||
| Financing | Short Term Borrowings | 0.00 | 0.00 | 0.00 | 0.00 | -- |
| Long Term Borrowings | 0.00 | 0.00 | 0.00 | 25.0M | ||
| Long Term Debt Reduction | -1.9M | -2.0M | -2.1M | -10.5M | ||
| Net Proceeds Stock Sale | 29.2M | 53.4M | 270.0K | 155.0K | ||
| Common Preferred Redeemed | 0.00 | 0.00 | 0.00 | 0.00 | -- | |
| Common Dividends | -- | -- | -- | -- | -- | |
| Cash Dividends Paid - Total | 0.00 | 0.00 | 0.00 | 0.00 | -- | |
| Other Sources - Financing | -7.4M | 0.00 | 0.00 | 0.00 | ||
| Other Uses - Financing | 0.00 | 0.00 | 0.00 | 0.00 | -- | |
| Net Cash Flow - Financing | 19.9M | 51.4M | -1.8M | 14.7M | ||
| Exchange Rate | Effect of Exchange Rate on Cash | -- | -- | -- | -- | -- |
| Net Change In Cash | 24.3M | 30.4M | -14.7M | -8.2M | ||
